{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:41:28Z","timestamp":1790224888626,"version":"4.1.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41582-025-01164-w","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:03:02Z","timestamp":1764237782000},"page":"182-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Towards primary prevention of multiple sclerosis"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2993-585X","authenticated-orcid":false,"given":"Ruth","family":"Dobson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2966-5335","authenticated-orcid":false,"given":"Karim L.","family":"Kreft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7737-5834","authenticated-orcid":false,"given":"J. William L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9299-0130","authenticated-orcid":false,"given":"Alison","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Nicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8128-6439","authenticated-orcid":false,"given":"Clare","family":"Walton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Narendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the UK MS Prevention Taskforce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasanee","family":"Braithwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Falahee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Gran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Grimsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Hemingway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Leach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"1164_CR1","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton, C. et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult. Scler. 26, 1816\u20131821 (2020).","journal-title":"Mult. Scler."},{"key":"1164_CR2","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1093\/brain\/aws099","volume":"135","author":"MT Wallin","year":"2012","unstructured":"Wallin, M. T. et al. The Gulf war era multiple sclerosis cohort: age and incidence rates by race, sex and service. Brain 135, 1778\u20131785 (2012).","journal-title":"Brain"},{"key":"1164_CR3","doi-asserted-by":"publisher","first-page":"e783","DOI":"10.1212\/WNL.0000000000011242","volume":"96","author":"T Kalincik","year":"2021","unstructured":"Kalincik, T. et al. Effect of disease-modifying therapy on disability in relapsing\u2013remitting multiple sclerosis over 15 years. Neurology 96, e783\u2013e797 (2021).","journal-title":"Neurology"},{"key":"1164_CR4","doi-asserted-by":"publisher","first-page":"e1215","DOI":"10.1212\/WNL.0000000000011461","volume":"96","author":"G Boffa","year":"2021","unstructured":"Boffa, G. et al. Long-term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis. Neurology 96, e1215\u2013e1226 (2021).","journal-title":"Neurology"},{"key":"1164_CR5","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1007\/s00415-020-09983-1","volume":"267","author":"B Steingo","year":"2020","unstructured":"Steingo, B. et al. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J. Neurol. 267, 3343\u20133353 (2020).","journal-title":"J. Neurol."},{"key":"1164_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S1474-4422(21)00179-4","volume":"20","author":"JWL Brown","year":"2021","unstructured":"Brown, J. W. L. et al. Safety and efficacy of bexarotene in patients with relapsing\u2013remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. Lancet Neurol. 20, 709\u2013720 (2021).","journal-title":"Lancet Neurol."},{"key":"1164_CR7","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","volume":"390","author":"AJ Green","year":"2017","unstructured":"Green, A. J. et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet 390, 2481\u20132489 (2017).","journal-title":"Lancet"},{"key":"1164_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneurol.2016.21","volume":"12","author":"A Winkelmann","year":"2016","unstructured":"Winkelmann, A., Loebermann, M., Reisinger, E. C., Hartung, H.-P. & Zettl, U. K. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat. Rev. Neurol. 12, 217\u2013233 (2016).","journal-title":"Nat. Rev. Neurol."},{"key":"1164_CR9","doi-asserted-by":"publisher","first-page":"e1810","DOI":"10.1212\/WNL.0000000000200150","volume":"98","author":"B Bebo","year":"2022","unstructured":"Bebo, B. et al. The economic burden of multiple sclerosis in the United States: estimate of direct and indirect costs. Neurology 98, e1810\u2013e1817 (2022).","journal-title":"Neurology"},{"key":"1164_CR10","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2023.2815","volume":"80","author":"C Lebrun-Fr\u00e9nay","year":"2023","unstructured":"Lebrun-Fr\u00e9nay, C. et al. Teriflunomide and time to clinical multiple sclerosis in patients with radiologically isolated syndrome. JAMA Neurol. 80, 1080 (2023).","journal-title":"JAMA Neurol."},{"key":"1164_CR11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ana.26555","volume":"93","author":"DT Okuda","year":"2023","unstructured":"Okuda, D. T. et al. Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome. Ann. Neurol. 93, 604\u2013614 (2023).","journal-title":"Ann. Neurol."},{"key":"1164_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1212\/WNL.0000000000003454","volume":"88","author":"NM Nielsen","year":"2017","unstructured":"Nielsen, N. M. et al. Neonatal vitamin D status and risk of multiple sclerosis. Neurology 88, 44\u201351 (2017).","journal-title":"Neurology"},{"key":"1164_CR13","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1001\/jamaneurol.2016.1463","volume":"73","author":"PM Rodr\u00edguez Cruz","year":"2016","unstructured":"Rodr\u00edguez Cruz, P. M. et al. Time- and region-specific season of birth effects in multiple sclerosis in the United Kingdom. JAMA Neurol. 73, 954 (2016).","journal-title":"JAMA Neurol."},{"key":"1164_CR14","doi-asserted-by":"publisher","first-page":"e2253","DOI":"10.1212\/WNL.0000000000012957","volume":"97","author":"RAA H\u00f8glund","year":"2021","unstructured":"H\u00f8glund, R. A. A. et al. Association of body mass index in adolescence and young adulthood and long-term risk of multiple sclerosis: a population-based study. Neurology 97, e2253\u2013e2261 (2021).","journal-title":"Neurology"},{"key":"1164_CR15","first-page":"160","volume":"19","author":"K Bjornevik","year":"2023","unstructured":"Bjornevik, K., M\u00fcnz, C., Cohen, J. I. & Ascherio, A. Epstein\u2013Barr virus as a leading cause of multiple sclerosis: mechanisms and implications. Nat. Rev. Neurol. 19, 160\u2013171 (2023).","journal-title":"Nat. Rev. Neurol."},{"key":"1164_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","volume":"13","author":"T Olsson","year":"2017","unstructured":"Olsson, T., Barcellos, L. F. & Alfredsson, L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat. Rev. Neurol. 13, 25\u201336 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"1164_CR17","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1002\/acn3.50862","volume":"6","author":"E Waubant","year":"2019","unstructured":"Waubant, E. et al. Environmental and genetic risk factors for MS: an integrated review. Ann. Clin. Transl. Neurol. 6, 1905\u20131922 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1164_CR18","doi-asserted-by":"publisher","first-page":"578202","DOI":"10.1016\/j.jneuroim.2023.578202","volume":"383","author":"HM Roshan","year":"2023","unstructured":"Roshan, H. M., Valadan, R., Hosseini, S. A. & Ajami, A. Specific antibodies to EBNA1 epitopes as risk factors for multiple sclerosis, a systematic review. J. Neuroimmunol. 383, 578202 (2023).","journal-title":"J. Neuroimmunol."},{"key":"1164_CR19","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000318","volume":"4","author":"R Dobson","year":"2017","unstructured":"Dobson, R., Kuhle, J., Middeldorp, J. & Giovannoni, G. Epstein\u2013Barr-negative MS: a true phenomenon? Neurol. Neuroimmunol. Neuroinflamm. 4, e318 (2017).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1164_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/1352458512449682","volume":"19","author":"J Pakpoor","year":"2013","unstructured":"Pakpoor, J. et al. The risk of developing multiple sclerosis in individuals seronegative for Epstein\u2013Barr virus: a meta-analysis. Mult. Scler. 19, 162\u2013166 (2013).","journal-title":"Mult. Scler."},{"key":"1164_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S1474-4422(14)70267-4","volume":"14","author":"L Belbasis","year":"2015","unstructured":"Belbasis, L., Bellou, V., Evangelou, E., Ioannidis, J. P. A. & Tzoulaki, I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol. 14, 263\u2013273 (2015).","journal-title":"Lancet Neurol."},{"key":"1164_CR22","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1093\/aje\/kwi280","volume":"162","author":"NM Nielsen","year":"2005","unstructured":"Nielsen, N. M. et al. Familial risk of multiple sclerosis: a nationwide cohort study. Am. J. Epidemiol. 162, 774\u2013778 (2005).","journal-title":"Am. J. Epidemiol."},{"key":"1164_CR23","doi-asserted-by":"publisher","first-page":"eaav7188","DOI":"10.1126\/science.aav7188","volume":"365","author":"International Multiple Sclerosis Genetics Consortium","year":"2019","unstructured":"International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 365, eaav7188 (2019).","journal-title":"Science"},{"key":"1164_CR24","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001007","volume":"8","author":"BM Jacobs","year":"2021","unstructured":"Jacobs, B. M. et al. Gene\u2013environment interactions in multiple sclerosis: a UK Biobank study. Neurol. Neuroimmunol. Neuroinflamm. 8, e1007 (2021).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1164_CR25","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/s41416-023-02450-4","volume":"129","author":"E Whitfield","year":"2023","unstructured":"Whitfield, E. et al. A taxonomy of early diagnosis research to guide study design and funding prioritisation. Br. J. Cancer 129, 1527\u20131534 (2023).","journal-title":"Br. J. Cancer"},{"key":"1164_CR26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1474-4422(17)30076-5","volume":"16","author":"JMA Wijnands","year":"2017","unstructured":"Wijnands, J. M. A. et al. Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. Lancet Neurol. 16, 445\u2013451 (2017).","journal-title":"Lancet Neurol."},{"key":"1164_CR27","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/ana.25247","volume":"83","author":"G Disanto","year":"2018","unstructured":"Disanto, G. et al. Prodromal symptoms of multiple sclerosis in primary care. Ann. Neurol. 83, 1162\u20131173 (2018).","journal-title":"Ann. Neurol."},{"key":"1164_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70175","author":"P Tank","year":"2025","unstructured":"Tank, P., Jacobs, B. M., Bestwick, J. & Dobson, R. Pre-diagnostic features of multiple sclerosis in a diverse UK cohort: a nested case\u2013control study. Ann. Clin. Transl. Neurol. https:\/\/doi.org\/10.1002\/acn3.70175 (2025).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1164_CR29","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","volume":"24","author":"X Montalban","year":"2025","unstructured":"Montalban, X. et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 24, 850\u2013865 (2025).","journal-title":"Lancet Neurol."},{"key":"1164_CR30","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/13524585241291471","volume":"31","author":"C Lebrun-Frenay","year":"2025","unstructured":"Lebrun-Frenay, C. et al. Analysis of healthcare utilization before the diagnosis of radiologically isolated syndrome. Mult. Scler. 31, 184\u2013196 (2025).","journal-title":"Mult. Scler."},{"key":"1164_CR31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1515\/cclm-2018-0400","volume":"57","author":"M Christiansen","year":"2018","unstructured":"Christiansen, M. et al. Cerebrospinal fluid free kappa light chains and kappa index perform equal to oligoclonal bands in the diagnosis of multiple sclerosis. Clin. Chem. Lab. Med. 57, 210\u2013220 (2018).","journal-title":"Clin. Chem. Lab. Med."},{"key":"1164_CR32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162\u2013173 (2018).","journal-title":"Lancet Neurol."},{"key":"1164_CR33","unstructured":"US National Library of Medicine. Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03783416 (2025)."},{"key":"1164_CR34","unstructured":"US National Library of Medicine. Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04466150 (2025)."},{"key":"1164_CR35","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1373\/clinchem.2007.089052","volume":"53","author":"D Franciotta","year":"2007","unstructured":"Franciotta, D. & Lolli, F. Interlaboratory reproducibility of isoelectric focusing in oligoclonal band detection. Clin. Chem. 53, 1557\u20131558 (2007).","journal-title":"Clin. Chem."},{"key":"1164_CR36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00415-024-12826-y","volume":"272","author":"D Vecchio","year":"2024","unstructured":"Vecchio, D. et al. Kappa index for multiple sclerosis diagnosis: an accurate biomarker of intrathecal synthesis. J. Neurol. 272, 30 (2024).","journal-title":"J. Neurol."},{"key":"1164_CR37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/1352458509352195","volume":"16","author":"G Calais","year":"2010","unstructured":"Calais, G. et al. Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. Mult. Scler. 16, 87\u201392 (2010).","journal-title":"Mult. Scler."},{"key":"1164_CR38","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3389\/fimmu.2019.01110","volume":"10","author":"MW H\u00fcmmert","year":"2019","unstructured":"H\u00fcmmert, M. W. et al. Investigation of oligoclonal IgG bands in tear fluid of multiple sclerosis patients. Front. Immunol. 10, 1110 (2019).","journal-title":"Front. Immunol."},{"key":"1164_CR39","first-page":"321","volume":"128","author":"R Dobson","year":"2013","unstructured":"Dobson, R., Topping, J., Davis, A., Thompson, E. & Giovannoni, G. Cerebrospinal fluid and urinary biomarkers in multiple sclerosis. Acta Neurol. Scand. 128, 321\u2013327 (2013).","journal-title":"Acta Neurol. Scand."},{"key":"1164_CR40","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","volume":"20","author":"M Khalil","year":"2024","unstructured":"Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders \u2014 towards clinical application. Nat. Rev. Neurol. 20, 269\u2013287 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"1164_CR41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/ana.27096","volume":"97","author":"P Benkert","year":"2024","unstructured":"Benkert, P. et al. Serum glial fibrillary acidic protein and neurofilament light chain levels reflect different mechanisms of disease progression under B-cell depleting treatment in multiple sclerosis. Ann. Neurol. 97, 104\u2013115 (2024).","journal-title":"Ann. Neurol."},{"key":"1164_CR42","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1212\/WNL.0000000000013016","volume":"98","author":"M Filippi","year":"2022","unstructured":"Filippi, M. et al. Performance of the 2017 and 2010 revised McDonald criteria in predicting MS diagnosis after a clinically isolated syndrome: a MAGNIMS study. Neurology 98, e1\u2013e14 (2022).","journal-title":"Neurology"},{"key":"1164_CR43","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(13)70103-0","volume":"12","author":"MP Sormani","year":"2013","unstructured":"Sormani, M. P. & Bruzzi, P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol. 12, 669\u2013676 (2013).","journal-title":"Lancet Neurol."},{"key":"1164_CR44","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","volume":"375","author":"K Bjornevik","year":"2022","unstructured":"Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein\u2013Barr virus associated with multiple sclerosis. Science 375, 296\u2013301 (2022).","journal-title":"Science"},{"key":"1164_CR45","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ana.24560","volume":"79","author":"Z Xia","year":"2016","unstructured":"Xia, Z. et al. Genes and environment in multiple sclerosis project: a platform to investigate multiple sclerosis risk. Ann. Neurol. 79, 178\u2013189 (2016).","journal-title":"Ann. Neurol."},{"key":"1164_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164992","volume":"11","author":"R Dobson","year":"2016","unstructured":"Dobson, R. et al. A risk score for predicting multiple sclerosis. PLoS ONE 11, e0164992 (2016).","journal-title":"PLoS ONE"},{"key":"1164_CR47","unstructured":"Chughtai, H. R. et al. An ultra-fast dementia diagnosis MRI protocol enabled by Wave-CAIPI. In ISMRM & ISMRT Annual Meeting & Exhibition abstr. 0416 https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.70341 (2023)."},{"key":"1164_CR48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/1754-9485.13744","volume":"69","author":"KJ de Jong","year":"2025","unstructured":"de Jong, K. J. et al. Incidental findings in research brain MRI: definition, prevalence and ethical implications. J. Med. Imaging Radiat. Oncol. 69, 35\u201345 (2025).","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"1164_CR49","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1007\/s10072-024-07402-1","volume":"45","author":"J Moura","year":"2024","unstructured":"Moura, J., Granziera, C., Marta, M. & Silva, A. M. Emerging imaging markers in radiologically isolated syndrome: implications for earlier treatment initiation. Neurol. Sci. 45, 3061\u20133068 (2024).","journal-title":"Neurol. Sci."},{"key":"1164_CR50","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1002\/acr.23179","volume":"69","author":"M Falahee","year":"2017","unstructured":"Falahee, M. et al. Patients\u2019 perceptions of their relatives\u2019 risk of developing rheumatoid arthritis and of the potential for risk communication, prediction, and modulation. Arthritis Care Res. 69, 1558\u20131565 (2017).","journal-title":"Arthritis Care Res."},{"key":"1164_CR51","doi-asserted-by":"publisher","first-page":"883287","DOI":"10.3389\/fimmu.2022.883287","volume":"13","author":"M Falahee","year":"2022","unstructured":"Falahee, M. & Raza, K. Perspectives of at-risk individuals on preventive intervention for rheumatoid arthritis: a mini review. Front. Immunol. 13, 883287 (2022).","journal-title":"Front. Immunol."},{"key":"1164_CR52","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/annrheumdis-2021-221160","volume":"81","author":"HJ Siddle","year":"2022","unstructured":"Siddle, H. J. et al. Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies. Ann. Rheum. Dis. 81, 159\u2013168 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1164_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/gps.70038","volume":"40","author":"A Thomson","year":"2025","unstructured":"Thomson, A. et al. Prevention is better than cure: public understanding of preventing neurodegenerative disorders. Int. J. Geriat. Psychiatry 40, e70038 (2025).","journal-title":"Int. J. Geriat. Psychiatry"},{"key":"1164_CR54","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","volume":"398","author":"M Falcaro","year":"2021","unstructured":"Falcaro, M. et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet 398, 2084\u20132092 (2021).","journal-title":"Lancet"},{"key":"1164_CR55","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.2015.15629","volume":"316","author":"R Chou","year":"2016","unstructured":"Chou, R., Dana, T., Blazina, I., Daeges, M. & Jeanne, T. L. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA 316, 2008\u20132024 (2016).","journal-title":"JAMA"},{"key":"1164_CR56","unstructured":"US National Library of Medicine. Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05787795 (2025)."},{"key":"1164_CR57","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200335","volume":"12","author":"J Britze","year":"2025","unstructured":"Britze, J. et al. Temporal dynamics of plasma neurofilament light in blood donors with preclinical multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 12, e200335 (2025).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1164_CR58","unstructured":"European pre-T1D registry.  Helmholtz Munich https:\/\/www.pre-t1d-registry.eu\/ (2025)."},{"key":"1164_CR59","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/13524585231208310","volume":"30","author":"NM Nielsen","year":"2024","unstructured":"Nielsen, N. M. et al. Smoking during pregnancy and risk of multiple sclerosis in offspring and mother: a Danish nationwide register-based cohort study. Mult. Scler. 30, 200\u2013208 (2024).","journal-title":"Mult. Scler."},{"key":"1164_CR60","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1136\/jnnp-2020-325676","volume":"92","author":"AK Hedstr\u00f6m","year":"2021","unstructured":"Hedstr\u00f6m, A. K. et al. DRB1-environment interactions in multiple sclerosis etiology: results from two Swedish case\u2013control studies. J. Neurol. Neurosurg. Psychiatry 92, 717\u2013722 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1164_CR61","unstructured":"Completed studies. Type 1 Diabetes TrialNet https:\/\/www.trialnet.org\/our-research\/completed-studies (2025)."},{"key":"1164_CR62","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"KC Herold","year":"2019","unstructured":"Herold, K. C. et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N. Engl. J. Med. 381, 603\u2013613 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1164_CR63","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.2337\/dc23-0350","volume":"46","author":"HK O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell, H. K. et al. Anxiety and risk perception in parents of children identified by population screening as high risk for type 1 diabetes. Diabetes Care 46, 2155\u20132161 (2023).","journal-title":"Diabetes Care"},{"key":"1164_CR64","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1002\/art.39297","volume":"67","author":"C Ramos-Remus","year":"2015","unstructured":"Ramos-Remus, C. et al. Autoantibodies in prediction of the development of rheumatoid arthritis among healthy relatives of patients with the disease. Arthritis Rheumatol. 67, 2837\u20132844 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"1164_CR65","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1136\/annrheumdis-2014-205227","volume":"74","author":"C Rakieh","year":"2015","unstructured":"Rakieh, C. et al. Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study. Ann. Rheum. Dis. 74, 1659\u20131666 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1164_CR66","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/art.40880","volume":"71","author":"S Tanner","year":"2019","unstructured":"Tanner, S. et al. A prospective study of the development of inflammatory arthritis in the family members of Indigenous North American people with rheumatoid arthritis. Arthritis Rheumatol. 71, 1494\u20131503 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"1164_CR67","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2337\/dc15-1419","volume":"38","author":"RA Insel","year":"2015","unstructured":"Insel, R. A. et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38, 1964\u20131974 (2015).","journal-title":"Diabetes Care"},{"key":"1164_CR68","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s00125-023-05955-y","volume":"66","author":"AM Luckett","year":"2023","unstructured":"Luckett, A. M. et al. Utility of genetic risk scores in type 1 diabetes. Diabetologia 66, 1589\u20131600 (2023).","journal-title":"Diabetologia"},{"key":"1164_CR69","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s41591-024-02938-3","volume":"30","author":"CR Zamecnik","year":"2024","unstructured":"Zamecnik, C. R. et al. An autoantibody signature predictive for multiple sclerosis. Nat. Med. 30, 1300\u20131308 (2024).","journal-title":"Nat. Med."},{"key":"1164_CR70","doi-asserted-by":"publisher","first-page":"eadj8094","DOI":"10.1126\/sciimmunol.adj8094","volume":"9","author":"V Kavaka","year":"2024","unstructured":"Kavaka, V. et al. Twin study identifies early immunological and metabolic dysregulation of CD8+ T cells in multiple sclerosis. Sci. Immunol. 9, eadj8094 (2024).","journal-title":"Sci. Immunol."},{"key":"1164_CR71","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1196\/annals.1447.054","volume":"1150","author":"JS Skyler","year":"2008","unstructured":"Skyler, J. S. et al. Type 1 diabetes TrialNet \u2014 an international collaborative clinical trials network. Ann. NY Acad. Sci. 1150, 14\u201324 (2008).","journal-title":"Ann. NY Acad. Sci."},{"key":"1164_CR72","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/acr.23841","volume":"72","author":"E Mosor","year":"2020","unstructured":"Mosor, E. et al. I would never take preventive medication! Perspectives and information needs of people who underwent predictive tests for rheumatoid arthritis. Arthritis Care Res. 72, 360\u2013368 (2020).","journal-title":"Arthritis Care Res."},{"key":"1164_CR73","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/annrheumdis-2017-212763","volume":"78","author":"DM Gerlag","year":"2019","unstructured":"Gerlag, D. M. et al. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Ann. Rheum. Dis. 78, 179\u2013185 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1164_CR74","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","volume":"403","author":"AP Cope","year":"2024","unstructured":"Cope, A. P. et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet 403, 838\u2013849 (2024).","journal-title":"Lancet"},{"key":"1164_CR75","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S0140-6736(19)32127-0","volume":"394","author":"CM Dayan","year":"2019","unstructured":"Dayan, C. M., Korah, M., Tatovic, D., Bundy, B. N. & Herold, K. C. Changing the landscape for type 1 diabetes: the first step to prevention. Lancet 394, 1286\u20131296 (2019).","journal-title":"Lancet"},{"key":"1164_CR76","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","volume":"390","author":"WK Huh","year":"2017","unstructured":"Huh, W. K. et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16\u201326 years: a randomised, double-blind trial. Lancet 390, 2143\u20132159 (2017).","journal-title":"Lancet"},{"key":"1164_CR77","doi-asserted-by":"publisher","first-page":"101157","DOI":"10.1016\/j.lanepe.2024.101157","volume":"49","author":"M Falcaro","year":"2025","unstructured":"Falcaro, M., Casta\u00f1\u00f3n, A., Ndlela, B. & Sasieni, P. Association between HPV vaccination and cervical screening policy changes and cervical cancer incidence and grade-3 cervical intraepithelial neoplasia incidence in England, 2006\u20132020: a population-based trends analysis. Lancet Reg. Health Eur. 49, 101157 (2025).","journal-title":"Lancet Reg. Health Eur."},{"key":"1164_CR78","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ypmed.2018.12.005","volume":"120","author":"C Stevens","year":"2019","unstructured":"Stevens, C., Vrinten, C., Smith, S. G., Waller, J. & Beeken, R. J. Acceptability of receiving lifestyle advice at cervical, breast and bowel cancer screening. Prev. Med. 120, 19\u201325 (2019).","journal-title":"Prev. Med."},{"key":"1164_CR79","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1111\/hex.13513","volume":"25","author":"S Groves","year":"2022","unstructured":"Groves, S. et al. Attitudes towards the integration of smoking cessation into lung cancer screening in the United Kingdom: a qualitative study of individuals eligible to attend. Health Expect. 25, 1703\u20131716 (2022).","journal-title":"Health Expect."},{"key":"1164_CR80","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/brain\/awab385","volume":"145","author":"J Rodgers","year":"2022","unstructured":"Rodgers, J. et al. The impact of smoking cessation on multiple sclerosis disease progression. Brain 145, 1368\u20131378 (2022).","journal-title":"Brain"},{"key":"1164_CR81","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28271","volume":"4","author":"C Lebrun-Fr\u00e9nay","year":"2021","unstructured":"Lebrun-Fr\u00e9nay, C. et al. Risk factors and time to clinical symptoms of multiple sclerosis among patients with radiologically isolated syndrome. JAMA Netw. Open 4, e2128271 (2021).","journal-title":"JAMA Netw. Open"},{"key":"1164_CR82","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41586-025-08800-x","volume":"641","author":"M Eyting","year":"2025","unstructured":"Eyting, M. et al. A natural experiment on the effect of herpes zoster vaccination on dementia. Nature 641, 438\u2013446 (2025).","journal-title":"Nature"},{"key":"1164_CR83","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S2468-1253(22)00389-2","volume":"8","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4\/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. Lancet Gastroenterol. Hepatol. 8, 145\u2013156 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1164_CR84","unstructured":"Octopus: optimal clinical trials platform for multiple sclerosis. MRC Clinical Trials Unit https:\/\/ms-octopus.mrcctu.ucl.ac.uk\/ (2024)."},{"key":"1164_CR85","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000200604","volume":"98","author":"V Li","year":"2022","unstructured":"Li, V. et al. Designing multi-arm multistage adaptive trials for neuroprotection in progressive multiple sclerosis. Neurology 98, 754\u2013764 (2022).","journal-title":"Neurology"},{"key":"1164_CR86","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1177\/17407745221093577","volume":"19","author":"IR White","year":"2022","unstructured":"White, I. R. et al. Combining factorial and multi-arm multi-stage platform designs to evaluate multiple interventions efficiently. Clin. Trials 19, 432\u2013441 (2022).","journal-title":"Clin. Trials"},{"key":"1164_CR87","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S2213-2600(21)00460-4","volume":"10","author":"BA Fisher","year":"2022","unstructured":"Fisher, B. A. et al. Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. Lancet Resp. Med. 10, 255\u2013266 (2022).","journal-title":"Lancet Resp. Med."},{"key":"1164_CR88","doi-asserted-by":"publisher","first-page":"101980","DOI":"10.1016\/j.eclinm.2023.101980","volume":"59","author":"M Del Giovane","year":"2023","unstructured":"Del Giovane, M. et al. Computerised cognitive assessment in patients with traumatic brain injury: an observational study of feasibility and sensitivity relative to established clinical scales. eClinicalMedicine 59, 101980 (2023).","journal-title":"eClinicalMedicine"},{"key":"1164_CR89","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209663","volume":"103","author":"FC Loonstra","year":"2024","unstructured":"Loonstra, F. C. et al. Association of polygenic risk score with lifetime risk of developing multiple sclerosis in a population-based birth-year cohort. Neurology 103, e209663 (2024).","journal-title":"Neurology"},{"key":"1164_CR90","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/brain\/awt356","volume":"137","author":"H Westerlind","year":"2014","unstructured":"Westerlind, H. et al. Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden. Brain 137, 770\u2013778 (2014).","journal-title":"Brain"},{"key":"1164_CR91","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/brain\/119.2.449","volume":"119","author":"NP Robertson","year":"1996","unstructured":"Robertson, N. P. et al. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain 119, 449\u2013455 (1996).","journal-title":"Brain"},{"key":"1164_CR92","doi-asserted-by":"publisher","first-page":"e1435","DOI":"10.1212\/WNL.0000000000005331","volume":"90","author":"DL Rotstein","year":"2018","unstructured":"Rotstein, D. L. et al. Temporal trends in multiple sclerosis prevalence and incidence in a large population. Neurology 90, e1435\u2013e1441 (2018).","journal-title":"Neurology"},{"key":"1164_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012496","volume":"5","author":"AE Handel","year":"2010","unstructured":"Handel, A. E. et al. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS ONE 5, e12496 (2010).","journal-title":"PLoS ONE"},{"key":"1164_CR94","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1177\/1352458520907901","volume":"26","author":"BM Jacobs","year":"2020","unstructured":"Jacobs, B. M., Giovannoni, G., Cuzick, J. & Dobson, R. Systematic review and meta-analysis of the association between Epstein\u2013Barr virus, multiple sclerosis and other risk factors. Mult. Scler. 26, 1281\u20131297 (2020).","journal-title":"Mult. Scler."},{"key":"1164_CR95","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.msard.2017.07.020","volume":"17","author":"ML Degelman","year":"2017","unstructured":"Degelman, M. L. & Herman, K. M. Smoking and multiple sclerosis: a systematic review and meta-analysis using the Bradford Hill criteria for causation. Mult. Scler. Relat. Disord. 17, 207\u2013216 (2017).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1164_CR96","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1093\/brain\/awm198","volume":"130","author":"Y Mikaeloff","year":"2007","unstructured":"Mikaeloff, Y., Caridade, G., Tardieu, M. & Suissa, S.KIDSEP Study group. Parental smoking at home and the risk of childhood-onset multiple sclerosis in children. Brain 130, 2589\u20132595 (2007).","journal-title":"Brain"},{"key":"1164_CR97","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.orcp.2024.11.005","volume":"18","author":"M Mohammadi","year":"2024","unstructured":"Mohammadi, M. et al. Abnormal body mass index is associated with risk of multiple sclerosis: a systematic review and meta-analysis. Obes. Res. Clin. Pract. 18, 311\u2013321 (2024).","journal-title":"Obes. Res. Clin. Pract."},{"key":"1164_CR98","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.3390\/ijerph15081726","volume":"15","author":"RM Lucas","year":"2018","unstructured":"Lucas, R. M. & Rodney Harris, R. M. On the nature of evidence and \u201cproving\u201d causality: Smoking and lung cancer vs. sun exposure, vitamin D and multiple sclerosis. Int. J. Environ. Res. Public. Health 15, 1726 (2018).","journal-title":"Int. J. Environ. Res. Public. Health"},{"key":"1164_CR99","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1212\/WNL.0b013e31820af93d","volume":"76","author":"RM Lucas","year":"2011","unstructured":"Lucas, R. M. et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 76, 540\u2013548 (2011).","journal-title":"Neurology"},{"key":"1164_CR100","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1001\/jamaneurol.2015.4800","volume":"73","author":"KL Munger","year":"2016","unstructured":"Munger, K. L. et al. Vitamin D status during pregnancy and risk of multiple sclerosis in offspring of women in the Finnish maternity cohort. JAMA Neurol. 73, 515\u2013519 (2016).","journal-title":"JAMA Neurol."},{"key":"1164_CR101","doi-asserted-by":"publisher","first-page":"105804","DOI":"10.1016\/j.msard.2024.105804","volume":"90","author":"NN Balasooriya","year":"2024","unstructured":"Balasooriya, N. N. et al. The association between vitamin D deficiency and multiple sclerosis: an updated systematic review and meta-analysis. Mult. Scler. Relat. Disord. 90, 105804 (2024).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1164_CR102","doi-asserted-by":"publisher","first-page":"110386","DOI":"10.1016\/j.envres.2020.110386","volume":"196","author":"Z Noorimotlagh","year":"2021","unstructured":"Noorimotlagh, Z., Azizi, M., Pan, H.-F., Mami, S. & Mirzaee, S. A. Association between air pollution and multiple sclerosis: a systematic review. Environ. Res. 196, 110386 (2021).","journal-title":"Environ. Res."},{"key":"1164_CR103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051506","volume":"7","author":"C Barrag\u00e1n-Mart\u00ednez","year":"2012","unstructured":"Barrag\u00e1n-Mart\u00ednez, C. et al. Organic solvents as risk factor for autoimmune diseases: a systematic review and meta-analysis. PLoS ONE 7, e51506 (2012).","journal-title":"PLoS ONE"},{"key":"1164_CR104","doi-asserted-by":"publisher","first-page":"106183","DOI":"10.1016\/j.msard.2024.106183","volume":"92","author":"ME Abouelmagd","year":"2024","unstructured":"Abouelmagd, M. E. et al. History of head trauma and the risk of multiple sclerosis: a systematic review and meta-analysis. Mult. Scler. Relat. Disord. 92, 106183 (2024).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1164_CR105","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1136\/jnnp-2024-335053","volume":"96","author":"CL de Mol","year":"2025","unstructured":"de Mol, C. L. et al. Environmental multiple sclerosis (MS) risk factors, genetic MS risk, and brain development in a general paediatric population. J. Neurol. Neurosurg. Psychiatry 96, 679\u2013685 (2025).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1164_CR106","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1177\/13524585251340812","volume":"31","author":"GK Zane","year":"2025","unstructured":"Zane, G. K. et al. The path to prevention of multiple sclerosis: considerations for Epstein\u2013Barr virus vaccine-based prevention studies. Mult. Scler. 31, 905\u2013915 (2025).","journal-title":"Mult. Scler."},{"key":"1164_CR107","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1086\/523813","volume":"196","author":"EM Sokal","year":"2007","unstructured":"Sokal, E. M. et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein\u2013Barr virus vaccine in healthy young adults. J. Infect. Dis. 196, 1749\u20131753 (2007).","journal-title":"J. Infect. Dis."},{"key":"1164_CR108","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1001\/jama.2025.1604","volume":"333","author":"E Thouvenot","year":"2025","unstructured":"Thouvenot, E. et al. High-dose vitamin D in clinically isolated syndrome typical of multiple sclerosis: the D-Lay MS randomized clinical trial. JAMA 333, 1413\u20131422 (2025).","journal-title":"JAMA"},{"key":"1164_CR109","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1093\/brain\/awad409","volume":"147","author":"H Butzkueven","year":"2024","unstructured":"Butzkueven, H. et al. Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome. Brain 147, 1206\u20131215 (2024).","journal-title":"Brain"},{"key":"1164_CR110","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41586-022-04427-4","volume":"603","author":"L Hosang","year":"2022","unstructured":"Hosang, L. et al. The lung microbiome regulates brain autoimmunity. Nature 603, 138\u2013144 (2022).","journal-title":"Nature"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01164-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01164-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01164-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:02:41Z","timestamp":1777291361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01164-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":110,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1164"],"URL":"https:\/\/doi.org\/10.1038\/s41582-025-01164-w","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"31 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of the article initially published, the Acknowledgements section was missing and has now been added to the HTML and PDF versions of the article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are members of the UK MS Prevention Taskforce. R.D. is a member of the Global MS Prevention Workshop steering group and has received funding from the National Multiple Sclerosis Society to study prodromal MS. R.D. and A.T. have received funding from the UK MS Society related to MS prevention. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}